A Phase 3, Randomized, Double-Blind Study Comparing ABT-494 to Placebo and to Adalimumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Who Are on a Stable Background of Methotrexate (MTX) and Who Have an Inadequate Response to MTX (MTX-IR)
Phase of Trial: Phase III
Latest Information Update: 11 Jul 2017
At a glance
- Drugs Upadacitinib (Primary) ; Adalimumab
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Acronyms SELECT-COMPARE
- Sponsors AbbVie
- 10 Jun 2017 Biomarkers information updated
- 02 May 2017 Planned End Date changed from 1 Aug 2020 to 14 Sep 2020.
- 11 Apr 2017 Planned End Date changed from 1 Sep 2020 to 1 Aug 2020.